-
1
المؤلفون: Victor Moreno, Noelia Nebot, Emmanuel Bouillaud, Dung-Yang Lee, Eva Muñoz-Couselo, Christina S. Won, Eduard Gasal
المساهمون: Institut Català de la Salut, [Nebot N, Lee DY, Gasal E] Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA. [Won CS] Novartis Institutes for BioMedical Research, East Hanover, New Jersey, USA. [Moreno V] START Madrid-FJD, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain. [Muñoz-Couselo E] Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Bouillaud E] Novartis Pharma AG, Basel, Switzerland, Vall d'Hebron Barcelona Hospital Campus
المصدر: Clinical Pharmacology in Drug Development
Scientiaمصطلحات موضوعية: Male, CYP3A4, CYP3A, Pharmaceutical Science, Pharmacology, 030226 pharmacology & pharmacy, fenómenos fisiológicos::fenómenos farmacológicos y toxicológicos::fenómenos farmacológicos::interacciones farmacológicas [FENÓMENOS Y PROCESOS], 0302 clinical medicine, Oximes, Medicine, fenómenos fisiológicos::fenómenos farmacológicos y toxicológicos::farmacocinética [FENÓMENOS Y PROCESOS], Cytochrome P-450 CYP3A, Pharmacology (medical), Drug Interactions, Rosuvastatin Calcium, OATP, Liver-Specific Organic Anion Transporter 1, Imidazoles, Articles, Middle Aged, Other subheadings::/pharmacology [Other subheadings], Physiological Phenomena::Pharmacological and Toxicological Phenomena::Pharmacokinetics [PHENOMENA AND PROCESSES], 030220 oncology & carcinogenesis, Area Under Curve, Female, pharmacokinetics, medicine.drug, Adult, Midazolam, Cmax, Original Manuscript, transporters, Chemical Actions and Uses::Pharmacologic Actions::Molecular Mechanisms of Pharmacological Action::Enzyme Inhibitors::Protein Kinase Inhibitors [CHEMICALS AND DRUGS], 03 medical and health sciences, Solute Carrier Organic Anion Transporter Family Member 1B3, Pharmacokinetics, Humans, Rosuvastatin, dabrafenib, Protein Kinase Inhibitors, drug interaction, Farmacocinètica, business.industry, acciones y usos químicos::acciones farmacológicas::mecanismos moleculares de acción farmacológica::inhibidores enzimáticos::inhibidores de proteínas cinasas [COMPUESTOS QUÍMICOS Y DROGAS], Dabrafenib, Drug interaction, Medicaments - Interacció, Proteïnes quinases - Inhibidors, Physiological Phenomena::Pharmacological and Toxicological Phenomena::Pharmacological Phenomena::Drug Interactions [PHENOMENA AND PROCESSES], Otros calificadores::/farmacología [Otros calificadores], business
وصف الملف: application/pdf
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7adef14bde6abca56c9d91bfe2b8074dTest
http://europepmc.org/articles/PMC8453865Test -
2
المؤلفون: Tycho Heimbach, Handan He, Christina S. Won, Felix Huth, Kenichi Umehara
المصدر: Biopharmaceutics & Drug Disposition. 39:152-163
مصطلحات موضوعية: Pharmacology, Physiologically based pharmacokinetic modelling, CYP3A4, business.industry, Cmax, virus diseases, Pharmaceutical Science, General Medicine, 030226 pharmacology & pharmacy, 03 medical and health sciences, 0302 clinical medicine, Pharmacokinetics, immune system diseases, In vivo, 030220 oncology & carcinogenesis, medicine, heterocyclic compounds, Pharmacology (medical), Ketoconazole, Ritonavir, Dosing, business, medicine.drug
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::25adfea51b5124afbaf648ccb44a0773Test
https://doi.org/10.1002/bdd.2122Test